A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection

Prof Michael Crooks m.g.crooks@hull.ac.uk
Professor of Respiratory Medicine

Development and application of a multi-scale computational model of sarcoidosis to predict therapeutic approaches for non-self-resolving disease Jun 30, 2017 - Aug 31, 2020
An in silico computational model of sarcoidosis

A single arm, open-label exploratory clinical trial of azithromycin in pulmonary sarcoidosis Mar 1, 2019 - Sep 30, 2020
Patients with sarcoidosis need treatment options that improve their disease without causing unacceptable side effects. Currently, steroids tablets are offered for severe sarcoidosis, but side effects can be dangerous and personally distressing, and s... Read More about A single arm, open-label exploratory clinical trial of azithromycin in pulmonary sarcoidosis.

BREEZE 2: A randomised controlled trial of a complex intervention to manage breathlessness in pulmonary fibrosis Apr 1, 2024 - Mar 31, 2026
Full trial based on BREEZE feasibility trial

HEIF: Simplifying patient information for clinical trials Aug 1, 2023 - Jul 31, 2024
Clinical trials are the main mechanism for improving patient care. They are an important source of income for the University and HUTH. The output in terms of publications and impact generated contributes greatly to the REF submission.

In order to... Read More about HEIF: Simplifying patient information for clinical trials.